Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Sedana Medical AB (publ) announces that the US Patent and Trademark Office (USPTO) has granted Sedana Medical a patent for the medical device Sedaconda ACD-S (US Patent No. 11,707,593 B2). The patent will run until 2037.
Sedaconda ACD-S is the main device in Sedana Medical's therapy for inhaled sedation of mechanically ventilated patients in intensive care units. With an estimated market potential of 10-12 billion SEK, the United States constitutes the largest potential commercial opportunity for Sedana Medical. The company is currently conducting the INSPiRE-ICU Phase III clinical program with a plan to submit the New Drug Application (NDA) to the FDA in Q1, 2025. The development program has been granted Fast Track Designation by the FDA.
"The Sedaconda ACD is the core of Sedana Medical's innovative inhaled sedation solution. I am very pleased that the US Patent and Trademark Office has granted our main device long-term patent protection in our most important future market", says Johannes Doll, CEO and President of Sedana Medical.
The Sedaconda ACD (Anaesthetic Conserving Device) contains an evaporator which enables vaporisation of inhaled anaesthetics, and the exhaled anaesthetic is reflected back to the patient, reducing the drug consumption. The Sedaconda ACD is also a very efficient Heat and Moisture Exchanger (HME) and contains a bacterial/viral filter.
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.